In the cutthroat world of cell and gene therapy manufacturing, RoslinCT isn't just building facilities—they're betting $72 million on a high-stakes transatlantic pivot. With just 5,300 monthly visitors, this is a company operating in the shadows of giants, yet scaling aggressively for a market that demands perfection.

"They're not selling software; they're selling the literal building blocks of life. In biotech, trust isn't built on SEO—it's built on sterile facilities and regulatory approvals."

The keyword 'casgevy' appearing in their data is telling. As the first FDA-approved CRISPR therapy, Casgevy represents the exact type of cutting-edge treatment RoslinCT aims to manufacture. This isn't coincidence—it's a signal of their positioning in the gene therapy space, targeting the most complex, high-value modalities where specialized manufacturing capabilities create moats.

• Dual-market strategy: Simultaneous US/EU expansion creates operational complexity but addresses regulatory fragmentation
• Clinical-to-commercial bridge: They're building infrastructure for both stages, solving the 'valley of death' in cell therapy scaling
• The Peter Coleman factor: CEO experience in scaling biotech operations suggests they're preparing for a liquidity event or major partnership